---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-057226"
form_type: "8-K"
ticker: "GPCR"
cik: "0001888886"
company_name: "Structure Therapeutics Inc."
filed_at: "2026-05-07T23:59:59+00:00"
generated_at: "2026-05-14T22:03:17.175696+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Structure Therapeutics Amends Sales Agreement to Raise ATM Capacity to $400M and Reports Q1 2026 Financials

## Summary
- Amended and restated Sales Agreement with Leerink Partners and Cantor Fitzgerald to remove aggregate offering limit and filed prospectus supplement increasing ATM by $150M to $400M.
- Aleniglipron Phase 2 ACCESS II achieved placebo-adjusted weight loss of 16.3% (39 lbs) at 180 mg and 16.0% (37 lbs) at 240 mg at 44 weeks.
- Cash, cash equivalents and short-term investments totaled $1.5 billion as of March 31, 2026; received $100M upfront license fee in Q1.
- FDA provided positive end-of-Phase 2 feedback; Phase 3 program for aleniglipron expected to initiate in Q3 2026.
- Net loss for Q1 2026 was $76.0 million, including $11.6 million non-cash share-based compensation.

## SEC filing metadata
- accession: 0001104659-26-057226
- form_type: 8-K
- ticker: GPCR
- cik: 0001888886
- company_name: Structure Therapeutics Inc.
- filed_at: 2026-05-07T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 1.01, 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1888886/000110465926057226/0001104659-26-057226-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1888886/000110465926057226/tm2613721d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-057226
- JSON: https://secwatch.observer/filing/0001104659-26-057226.json
- Plain text: https://secwatch.observer/filing/0001104659-26-057226.txt

## Source-grounded claims
- claim_id: d03eb025238609f96a6ab68cd79971940f014504
  claim: Structure Therapeutics Inc. reported financial results for the first quarter ended March 31, 2026.
  evidence_excerpt: Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, with a focus on obesity, today reported financial results for the first quarter ended March 31, 2026, and provided a business update.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1888886/000110465926057226/0001104659-26-057226-index.htm
- claim_id: 870d62963ed5eac350b3fc4d85c59218de766582
  claim: Structure Therapeutics Inc. amended Amended and Restated Sales Agreement with Leerink Partners LLC and Cantor Fitzgerald & Co. (effective 2026-05-07).
  evidence_excerpt: On May 7, 2026, Structure Therapeutics Inc. (the “Company”) amended and restated that certain Sales Agreement dated August 6, 2025 (the “Sales Agreement” and as amended and restated, the “Amended and Restated Sales Agreement”) with Leerink Partners LLC and Cantor Fitzgerald & Co. (collectively, the “Sales Agents”), relating to the offer and sale of the Company’s American Depositary Shares (“ADSs”), each representing three ordinary shares, $0.0001 par value per ordinary share.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1888886/000110465926057226/0001104659-26-057226-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.